Brief: Sellas Announces Positive Topline Data From GFH009 Phase 1 Dose-Escalation Trial
04/05/2023 13:42
May 4 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS ANNOUNCES POSITIVE TOPLINE DATA FROM GFH009 PHASE 1
DOSE-ESCALATION TRIAL IN ACUTE MYELOID LEUKEMIA COHORT
SUPPORTING ADVANCEMENT TO PHASE 2 CLINICAL STUDY
* SELLAS LIFE SCIENCES - ALL KEY STUDY OBJECTIVES REGARDING
PHARMACOKINETIC (PK), PHARMACODYNAMIC (PD), SAFETY AND CLINICAL
ACTIVITY DATA WERE MET
Source text for Eikon: ID:nGNX6rTQb3
Further company coverage: SLS.O
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses